Infinity Bio

What Infinity Bio does

Infinity Bio, Inc. is a Baltimore-based biotechnology company (founded 2023 as a Johns Hopkins Fast Forward Company) that provides fee-for-service antibody reactome profiling for academic researchers, government public-health programs, and biopharma companies. Its proprietary MIPSA (Molecular Indexing of Proteins by Self-Assembly) platform covalently attaches DNA barcodes to peptide or full-length protein antigens via a HaloTag-based self-assembly reaction during in vitro translation, enabling solution-phase antibody-antigen binding, magnetic-bead capture, and NGS decoding of reactivity repertoires. The company monetizes a portfolio of SIGHT-branded assays — VirSIGHT (human virome), EnviroSIGHT (allergens and environmental antigens, including AllerSIGHT), HuSIGHT (combined full-length and peptide human autoantibody profiling), and MuSIGHT (mouse proteome) — plus mAb Characterization for therapeutic antibody off-target profiling, Custom Antigen Libraries, and fee-for-service bioinformatics consulting. Pricing is quote-based and not publicly disclosed; every project includes four hours of bioinformatics consultation, with additional hours available as a paid add-on. Distribution is enterprise-direct (with a newly appointed commercial CEO and VP of BD & Sales) augmented by a regional channel partnership with the Austrian Institute of Technology for Europe. The business has been backed by $12.5M of disclosed funding across a 2024 SEC Form D and a 2025 $8M Series A led by Illumina Ventures, and acquired the assets of Serimmune in June 2025 to consolidate complementary antibody-repertoire IP.

Name

Infinity Bio

Legal name

Infinity Bio, Inc.

Website

https://infinitybio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Infinity Bio is a Baltimore-based biotech offering fee-for-service antibody reactome profiling for academic researchers, government agencies, biopharma, and animal-health companies using its proprietary MIPSA molecular-display platform and SIGHT-branded assay portfolio.

Ownership category

akta.pro rank

Product category

Antibody Profiling and Immunoassay Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• Antibody reactome profiling
• Immune repertoire analysis
• Immunoassay services
• Biopharmaceutical contract research
• Autoantibody discovery

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Services / Antibody Reactome Profiling: Infinity Bio generates revenue by providing fee-for-service antibody reactome profiling assays. Customers submit biological samples (serum, plasma, or other fluids) and receive comprehensive antibody reactivity reports. Services include VirSIGHT (virome), EnviroSIGHT (environmental/allergen), HuSIGHT (human autoantibodies), MuSIGHT (mouse models), AllerSIGHT (allergen-specific), mAb Characterization, and Custom Antigen Libraries. Pricing is quote-based, varying by project scope, library size, number of samples, and informatics requirements. Additional bioinformatics consulting is available as a fee-for-service add-on beyond the included 4 hours per project.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Infinity Bio provides fee-for-service antibody reactome profiling assays using its proprietary MIPSA technology, allowing customers to submit biological samples and receive comprehensive antibody reactivity reports across virome, environmental, human autoantibody, and mouse protein antigen libraries. The platform is complemented by monoclonal antibody characterization, custom antigen library design, and bioinformatics analysis services, with every project including four hours of custom informatics consultation.

Product overview

Infinity Bio is a biotechnology company offering antibody reactome profiling services powered by its proprietary MIPSA (Molecular Indexing of Proteins by Self-Assembly) technology platform. The product portfolio centers on MIPSA as the core enabling technology, with specialized SIGHT-branded assay services including VirSIGHT (human virome), EnviroSIGHT (environmental/allergen exposures), HuSIGHT (human proteins/autoimmunity), and MuSIGHT (mouse proteins for preclinical research). AllerSIGHT for allergen-specific profiling is now integrated into EnviroSIGHT. The platform is complemented by specialized services including mAb Characterization for off-target binding analysis, Custom Antigen Libraries for bespoke research needs, and Bioinformatics & Data Analysis for statistical consulting. The company also offers Quality & Lab Automation services and utilizes proprietary VeraCode technology for library barcoding accuracy.

Differentiator

Problem solved

Functional benefit

Products and services

• MIPSA (Molecular Indexing of Proteins by Self-Assembly) Proprietary molecular display technology that enables comprehensive antibody reactome profiling using self-assembly of DNA-barcoded peptide and protein libraries; combines peptide and full-length protein antigens in a single solution-phase assay for research and biopharma customers.
• VirSIGHT Human virome antibody reactome profiler providing comprehensive peptide-level library coverage of all 529 species-level eukaryotic viruses known to infect humans, including 2,381,603 protein sequences represented as 285,669 unique peptides.
• EnviroSIGHT Environmental exposure antibody reactome profiler covering the world's largest panel of allergens and non-viral/microbial antigens, including 1,207 genera, 3,437 unique taxonomic IDs, and 31,133 unique protein antigens and allergens represented as 242,884 unique peptides.
• HuSIGHT Human protein antibody reactome profiler and the world's only combined full-length protein and peptide tile library for human autoantibody profiling: 27,703 unique genes, 385,432 unique protein isoforms, 16,516 unique full-length proteins from ThermoFisher's Ultimate ORFeome, and 353,034 unique peptides.
• MuSIGHT Mouse protein antibody reactome profiler providing comprehensive peptide library coverage of all mouse proteins, including 26,713 unique genes, 176,362 unique protein isoforms tiled as 273,786 unique peptides, plus 2,164 full-length mature secreted protein isoforms.
• AllerSIGHT Allergen antibody reactome profiler providing the most comprehensive peptide-based allergen library covering all known food and environmental allergens from 501 species-level organisms, with 4,463 protein sequences and 29,775 unique peptides.
• mAb Characterization Cross-reactivity, target identification, and off-target binding analysis service for monoclonal and polyclonal antibodies, enabling proteome-wide specificity profiling to identify lead mAbs with deleterious off-target binding prior to IND filing.
• Custom Antigen Libraries Bespoke library design service covering any set of protein sequences from any organism including bacteria, fungi, parasites, plants, and viruses, enabling deep mutational scanning, epitope fine-mapping, and off-target prediction with rapid 4-6 week turnaround.

Quantifiable outcome

• Up to 20% of lead monoclonal antibodies display deleterious off-target binding that can be detected by unbiased proteome-wide specificity profiling prior to IND filing
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature9 records

Partnerships

Eight partnerships are on record, tiered core, strategic and supporting.

• Austrian Institute of Technology (AIT)coreChannel Partner/ Reseller/ Distributor · 13 August 2025Infinity Bio partnered with the Austrian Institute of Technology to provide access to antibody reactome profiling services in Europe. AIT serves as a regional channel partner enabling European researchers to access Infinity Bio's MIPSA-based services without needing to engage the company directly from the US. This is the company's first named channel partnership for geographic expansion.
• Johns Hopkins University / Fast Forward ProgramcoreStrategic or Co-development PartnerInfinity Bio's MIPSA technology was originally developed in Dr. H. Benjamin Larman's Laboratory of Precision Immunology at Johns Hopkins School of Medicine's Pathology Department. Infinity Bio is a Johns Hopkins Fast Forward Company, indicating an ongoing institutional relationship for technology commercialization and academic collaboration.
• ThermoFisher ScientificstrategicTechnology or IntegrationThermoFisher Scientific's sequence-verified Ultimate ORFeome (containing 16,516 unique proteins) serves as the source of the HuSIGHT-Full_Length sublibrary. This provides the foundation for Infinity Bio's combined peptide and full-length human autoantibody profiling assay. The relationship involves use of ThermoFisher's published ORF collection as library input.
• Twist BiosciencesupportingTechnology or IntegrationTwist Bioscience is listed among Infinity Bio's partners. Twist provides synthetic DNA oligonucleotide libraries, which are used as an input for MIPSA's peptide library construction process. The partnership enables Infinity Bio to access high-quality synthetic DNA for its library synthesis operations.
• NextmunesupportingChannel Partner/ Reseller/ DistributorNextmune, a Stockholm-based animal health company, uses Infinity Bio's MIPSA technology to rapidly characterize the allergome of companion animal species. This collaboration allows Nextmune to advance its R&D pipeline in veterinary allergy diagnostics and therapeutics. Thierry Olivry, Head of R&D at Nextmune, provided a testimonial endorsing the MIPSA technology.
• BenchlingsupportingTechnology or IntegrationBenchling is a life sciences R&D software platform listed among Infinity Bio's clients and partners. The partnership likely involves using Benchling's cloud-based R&D platform for sample tracking, experiment management, or data analysis workflows within Infinity Bio's laboratory operations.
• PsomagensupportingTechnology or IntegrationPsomagen, a genomics services company, is listed as a partner of Infinity Bio. The relationship likely involves Next Generation Sequencing (NGS) services, as Infinity Bio's MIPSA platform relies on NGS to decode DNA-barcoded antigen repertoires after antibody immunocapture.
• IlluminasupportingTechnology or IntegrationIllumina provides the DNA sequencing platform used to read MIPSA barcodes after antibody capture. Infinity Bio's MIPSA workflow relies on Illumina's NGS technology for high-throughput barcode counting, which is central to the platform's data generation. Illumina Ventures (the VC arm) is separately a financial backer.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/infinity-bio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infinity Bio